BioStem Technologies produces innovative amniotic membrane and umbilical cord tissue-based allografts, RHEO™, OROPRO™, AEON™, VENDAJE™, VENDAJE™ AC, and VENDAJE™ OPTIC.
Our allografts are processed with our proprietary processing method that preserves the biologic quality of the tissue.
In our AATB® accredited, FDA registered, cGMP compliant lab, we strive to provide products and services that adhere to Current Good Tissue Practice requirements.
Who We Are
BioStem Technologies is a pre-clinical-stage biotechnology company focused on harnessing elements of perinatal tissue to repair or reverse damage caused by a broad range of degenerative diseases.
Our allografts are processed utilizing our proprietary BioRetain™ method, which focuses on preserving the tissue's endogenous biological properties while maintaining the structure and matrix found in fresh perinatal tissue.
BioStem is committed to improving patients' quality of life through scientific innovation and strict adherence to our quality system.
Through innovation, quality, and compassion, we deliver leading-edge products by focusing on collaboration, education, and special initiatives.